日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease

血清成纤维细胞生长因子21是慢性肝病恶病质的一种新型生物标志物。

Tanaka, Takatsugu; Suda, Goki; Ohara, Masatsugu; Maehara, Osamu; Yoda, Tomoka; Fu, Qingjie; Yang, Zijian; Yasuura, Naohiro; Meno, Akimitsu; Sasaki, Takashi; Kohya, Risako; Kitagataya, Takashi; Kawagishi, Naoki; Nakai, Masato; Sho, Takuya; Ohnishi, Shunsuke; Sakamoto, Naoya

Genetic ablation of interleukin-17A augments fibrosis in a mouse model of cholestatic liver injury

基因敲除白细胞介素-17A可加剧胆汁淤积性肝损伤小鼠模型的纤维化。

Kitagataya, Takashi; Krishnan, Anuradha; Olson, Kirsta E; Gutierrez, Florencia; Baez-Faria, Michelle; Guicciardi, Maria Eugenia; Pavelko, Kevin D; Azad, Adiba I; Gores, Gregory J

Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study

长链非编码RNA PWRN4与SVR后肝细胞癌相关:一项全基因组关联研究

Suda, Goki; Sugiyama, Masaya; Hikita, Hayato; Nishio, Akira; Tatsumi, Tomohide; Takehara, Tetsuo; Murakawa, Miyako; Nakagawa, Mina; Asahina, Yasuhiro; Mizokami, Masashi; Kakisaka, Tatsuhiko; Sakamoto, Yuzuru; Taketomi, Akinobu; Miyanishi, Koji; Ueno, Yoshiyuki; Haga, Hiroaki; Maekawa, Shinya; Enomoto, Nobuyuki; Kurosaki, Masayuki; Kohjima, Motoyuki; Nakamuta, Makoto; Tanaka, Yasuhito; Yamamoto, Yoshiya; Baba, Masaru; Hanamatsu, Hisatoshi; Furukawa, Jun-Ichi; Ohara, Masatsugu; Kitagataya, Takashi; Kawagishi, Naoki; Nakai, Masato; Sho, Takuya; Ogawa, Koji; Sakamoto, Naoya

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.

血清 FGF21 作为预测 HCC 对阿特珠单抗和贝伐珠单抗反应的指标

Kohya Risako, Suda Goki, Ohara Masatsugu, Hosoda Shunichi, Sho Takuya, Chuma Makoto, Komori Atsumasa, Kugiyama Yuki, Yasui Yutaka, Tsuchiya Kaoru, Kurosaki Masayuki, Tani Joji, Kaneko Shun, Nakagawa Mina, Asahina Yasuhiro, Maekawa Shinya, Enomoto Nobuyuki, Yamamoto Yoshiya, Baba Masaru, Yamada Ren, Sasaki Takashi, Yoda Tomoka, Yoshida Sonoe, Fu Qingjie, Yang Zijian, Maehara Osamu, Ohnishi Shunsuke, Tokuchi Yoshimasa, Kitagataya Takashi, Kawagishi Naoki, Nakai Masato, Natsuizaka Mitsuteru, Ogawa Koji, Sakamoto Naoya

Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort

基于对前瞻性多中心队列的回顾性分析,简化日本慢性丙型肝炎患者索非布韦/维帕他韦的监测

Suda, Goki; Baba, Masaru; Yamamoto, Yoshiya; Yoshida, Sonoe; Muranaka, Tetsuhito; Meguro, Takashi; Terashita, Katsumi; Ito, Jun; Kobayashi, Tomoe; Izumi, Takaaki; Takagi, Tomofumi; Hosoda, Shunichi; Yamada, Ren; Fu, Qingjie; Yang, Zijian; Yokoyama, Daisuke; Tanaka, Takatsugu; Meno, Akimitsu; Yasuura, Naohiro; Kitagataya, Takashi; Ohara, Masatsugu; Kawagishi, Naoki; Nakai, Masato; Sho, Takuya; Ogawa, Koji; Sakamoto, Naoya

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) deletion in myeloid cells augments cholestatic liver injury

髓系细胞中肿瘤坏死因子相关凋亡诱导配体 (TRAIL) 的缺失会加剧胆汁淤积性肝损伤。

Anuradha Krishnan ,Nazli Begum Ozturk ,Kaiyel A Cutshaw ,Maria Eugenia Guicciardi ,Takashi Kitagataya ,Kirsta E Olson ,Kevin D Pavelko ,William Sherman ,Alexander Q Wixom ,Nidhi Jalan-Sakrikar ,Michelle Baez-Faria ,Florencia Gutierrez ,Gregory J Gores

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.

基线 CXCL9 水平低可预测接受 Atezolizumab 联合 Bevacizumab 治疗的不可切除 HCC 患者的早期疾病进展

Hosoda Shunichi, Suda Goki, Sho Takuya, Ogawa Koji, Kimura Megumi, Yang Zijian, Yoshida Sonoe, Kubo Akinori, Tokuchi Yoshimasa, Kitagataya Takashi, Maehara Osamu, Ohnishi Shunsuke, Nakamura Akihisa, Yamada Ren, Ohara Masatsugu, Kawagishi Naoki, Natsuizaka Mitsuteru, Nakai Masato, Morikawa Kenichi, Furuya Ken, Baba Masaru, Yamamoto Yoshiya, Suzuki Kazuharu, Izumi Takaaki, Meguro Takashi, Terashita Katsumi, Ito Jun, Miyagishima Takuto, Sakamoto Naoya

Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma

肌肉萎缩和皮下脂肪组织放射密度增高同时存在预示着肝细胞癌预后不良。

Ohara, Masatsugu; Suda, Goki; Kohya, Risako; Sasaki, Takashi; Yoda, Tomoka; Yoshida, Sonoe; Fu, Qingjie; Yang, Zijian; Hosoda, Shunichi; Maehara, Osamu; Ohnishi, Shunsuke; Tokuchi, Yoshimasa; Kitagataya, Takashi; Kawagishi, Naoki; Nakai, Masato; Sho, Takuya; Natsuizaka, Mitsuteru; Ogawa, Koji; Sakamoto, Naoya

Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma

不可切除肝细胞癌患者对阿特珠单抗联合贝伐珠单抗治疗产生耐药性期间血清生长因子的变化

Yang, Zijian; Suda, Goki; Maehara, Osamu; Ohara, Masatsugu; Yoda, Tomoka; Sasaki, Takashi; Kohya, Risako; Yoshida, Sonoe; Hosoda, Shunichi; Tokuchi, Yoshimasa; Kitagataya, Takashi; Suzuki, Kazuharu; Kawagishi, Naoki; Nakai, Masato; Sho, Takuya; Natsuizaka, Mitsuteru; Ogawa, Koji; Ohnishi, Shunsuke; Sakamoto, Naoya

Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma.

血清 FGF21 水平变化与 Lenvatinib 诱导的不可切除肝细胞癌患者食欲丧失之间可能存在相关性

Kohya Risako, Suda Goki, Ohara Masatsugu, Sasaki Takashi, Yoda Tomoka, Sakurai Naofumi, Yoshida Sonoe, Fu Qingjie, Yang Zijian, Hosoda Shunichi, Maehara Osamu, Ohnishi Shunsuke, Tokuchi Yoshimasa, Kitagataya Takashi, Suzuki Kazuharu, Kawagishi Naoki, Nakai Masato, Sho Takuya, Natsuizaka Mitsuteru, Ogawa Koji, Sakamoto Naoya